logo
Share SHARE
FONT-SIZE Plus   Neg

Life Technologies Showcases Leading Technologies For Cancer Research At AACR

Life Technologies Corp. (LIFE) said it will exhibit products across the spectrum of basic, translational and clinical cancer research during the American Association of Cancer Research or AACR Annual Meeting 2012, taking place March 31 - April 4, in Chicago, Illinois.

Presentations included in this exhibition are triple negative breast cancer, Semiconductor sequencing of melanoma samples, the company said.

Triple negative breast tumors, which make up nearly 20 percent of breast cancers, do not respond to treatment with targeted therapies such as Herceptin. To investigate new options for these patients, the first clinical trial of whole-genome sequencing for women with triple negative breast cancer was initiated in March 2010; early results will be presented by John Carpten, head of the Integrated Cancer Genomics Division at the Phoenix-based Translational Genomics Research Institute or Tgen.

In addition, George Watts, research assistant professor and co-director of the Genomics Shared Service at The University of Arizona Cancer Center, will present a poster demonstrating accurate, cost-effective sequencing of six commonly mutated genes in archived research samples from metastatic melanoma patients using the Life Technologies Ion Personal Genome Machine system.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Best Buy Co., Inc. (BBY) reported first-quarter non-GAAP earnings per share from continuing operations of $0.44, an increase of 19% from $0.37, a year ago. On average, 21 analysts polled by Thomson Reuters expected the company to report profit per share of $0.35 for the quarter. Analysts' estimates typically... Automotive parts retailer AutoZone, Inc. on Tuesday reported a 6 percent increase in profit for the third quarter from last year, reflecting growth in sales and higher inventory on new store openings. However, both revenue and earnings per share for the quarter missed analysts' expectations. Toll Brothers, Inc. (TOL), the nation's leading builder of luxury homes, reported second-quarter net income of $89.1 million, or $0.51 per share, compared to $67.9 million, or $0.37 per share, prior year. Pre-tax income increased to $140.4 million from $86.5 million. On average, 18 analysts polled by...
comments powered by Disqus
Follow RTT